This company has been marked as potentially delisted and may not be actively trading. Nightstar Therapeutics (NITE) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock NITE vs. KRYS, PCVX, SWTX, ACLX, CRSP, ALVO, SRRK, IMVT, IBRX, and VCELShould you be buying Nightstar Therapeutics stock or one of its competitors? The main competitors of Nightstar Therapeutics include Krystal Biotech (KRYS), Vaxcyte (PCVX), SpringWorks Therapeutics (SWTX), Arcellx (ACLX), CRISPR Therapeutics (CRSP), Alvotech (ALVO), Scholar Rock (SRRK), Immunovant (IMVT), ImmunityBio (IBRX), and Vericel (VCEL). These companies are all part of the "medical" sector. Nightstar Therapeutics vs. Krystal Biotech Vaxcyte SpringWorks Therapeutics Arcellx CRISPR Therapeutics Alvotech Scholar Rock Immunovant ImmunityBio Vericel Krystal Biotech (NASDAQ:KRYS) and Nightstar Therapeutics (NASDAQ:NITE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, community ranking, media sentiment and dividends. Does the MarketBeat Community favor KRYS or NITE? Krystal Biotech received 74 more outperform votes than Nightstar Therapeutics when rated by MarketBeat users. However, 69.88% of users gave Nightstar Therapeutics an outperform vote while only 67.80% of users gave Krystal Biotech an outperform vote. CompanyUnderperformOutperformKrystal BiotechOutperform Votes29967.80% Underperform Votes14232.20% Nightstar TherapeuticsOutperform Votes22569.88% Underperform Votes9730.12% Does the media favor KRYS or NITE? In the previous week, Krystal Biotech had 12 more articles in the media than Nightstar Therapeutics. MarketBeat recorded 12 mentions for Krystal Biotech and 0 mentions for Nightstar Therapeutics. Krystal Biotech's average media sentiment score of 1.20 beat Nightstar Therapeutics' score of 0.00 indicating that Krystal Biotech is being referred to more favorably in the media. Company Overall Sentiment Krystal Biotech Positive Nightstar Therapeutics Neutral Do analysts prefer KRYS or NITE? Krystal Biotech currently has a consensus price target of $211.13, suggesting a potential upside of 69.96%. Given Krystal Biotech's stronger consensus rating and higher probable upside, equities analysts clearly believe Krystal Biotech is more favorable than Nightstar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Krystal Biotech 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Nightstar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation and earnings, KRYS or NITE? Krystal Biotech has higher revenue and earnings than Nightstar Therapeutics. Nightstar Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKrystal Biotech$333.45M10.77$10.93M$4.1629.86Nightstar TherapeuticsN/AN/A-$36.86M-$1.26-23.47 Which has more risk & volatility, KRYS or NITE? Krystal Biotech has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Nightstar Therapeutics has a beta of 2.84, indicating that its share price is 184% more volatile than the S&P 500. Do institutionals and insiders believe in KRYS or NITE? 86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 32.8% of Nightstar Therapeutics shares are held by institutional investors. 13.7% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is KRYS or NITE more profitable? Krystal Biotech has a net margin of 30.69% compared to Nightstar Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 11.41% beat Nightstar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Krystal Biotech30.69% 11.41% 10.40% Nightstar Therapeutics N/A -30.89%-27.65% SummaryKrystal Biotech beats Nightstar Therapeutics on 16 of the 18 factors compared between the two stocks. Get Nightstar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NITE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NITE vs. The Competition Export to ExcelMetricNightstar TherapeuticsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$991.74M$2.92B$5.33B$8.35BDividend YieldN/A1.63%5.20%4.10%P/E Ratio-23.4731.0326.7419.65Price / SalesN/A392.32394.49119.78Price / CashN/A168.6838.3234.62Price / Book5.023.206.744.50Net Income-$36.86M-$72.35M$3.23B$248.32M Nightstar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NITENightstar TherapeuticsN/A$29.57+0.3%N/A+16.0%$991.74MN/A-23.4747KRYSKrystal Biotech4.9033 of 5 stars$135.47-2.8%$218.63+61.4%-26.0%$3.91B$333.45M45.31210Positive NewsPCVXVaxcyte3.0749 of 5 stars$30.34-4.0%$136.50+349.9%-52.4%$3.91BN/A-6.60160Positive NewsSWTXSpringWorks Therapeutics2.3646 of 5 stars$46.22+0.2%$52.57+13.7%+4.5%$3.47B$191.59M-13.28230Positive NewsACLXArcellx1.623 of 5 stars$58.84-1.1%$109.31+85.8%+20.2%$3.24B$76.81M-82.8780Gap DownCRSPCRISPR Therapeutics3.0075 of 5 stars$37.13-1.2%$71.75+93.2%-33.9%$3.21B$35M-8.50473Trending NewsAnalyst ForecastAnalyst RevisionGap DownALVOAlvotech1.7564 of 5 stars$10.54+2.8%$18.00+70.8%-29.0%$3.18B$489.68M-5.704High Trading VolumeSRRKScholar Rock3.981 of 5 stars$31.36-3.4%$42.67+36.1%+160.1%$2.97B$33.19M-13.34140IMVTImmunovant2.6837 of 5 stars$14.19-2.5%$38.33+170.1%-50.7%$2.41BN/A-5.42120Positive NewsGap DownIBRXImmunityBio1.8395 of 5 stars$2.54+7.6%$12.19+379.8%-61.4%$2.24B$14.75M-2.76590Analyst UpgradeGap DownHigh Trading VolumeVCELVericel2.6726 of 5 stars$44.07+3.3%$60.86+38.1%-17.8%$2.21B$238.54M734.62300Positive NewsAnalyst ForecastGap Down Related Companies and Tools Related Companies KRYS Alternatives PCVX Alternatives SWTX Alternatives ACLX Alternatives CRSP Alternatives ALVO Alternatives SRRK Alternatives IMVT Alternatives IBRX Alternatives VCEL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NITE) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nightstar Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Nightstar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NITE Stock Free NITE Stock Alerts